Get started
Atossa Therapeutics, Inc.AA

Atossa Therapeutics, Inc.

0.9066USDR
+0.0066+0.73%
As of today at 16:57 GMT
USD
No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

ATOS chart


Full chart

ATOS upcoming earnings


Next report date
≈
August 18
Report period
Q2 2025
EPS estimate
−0.06 USD
Revenue estimate
0.00 USD

Key stats


Market capitalization
‪117.11 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.2077 USD
Net income (FY)
‪−25.50 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪129.12 M‬
Beta (1Y)
2.39

Employees


Employees (FY)
15
Change (1Y)
+3 +25.00%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.70 M‬ USD

About Atossa Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Steven C. Quay
Website
atossatherapeutics.com
Headquarters
Seattle
Founded
2008
FIGI
BBG002NCD8C8
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Financials


Performance
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−8.00 M‬‬
‪‪−6.00 M‬‬
‪‪−4.00 M‬‬
‪‪−2.00 M‬‬
‪0.00‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−8.00 M‬‬
‪‪−6.00 M‬‬
‪‪−4.00 M‬‬
‪‪−2.00 M‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−6.80 M‬‬
‪‪−5.10 M‬‬
‪‪−3.40 M‬‬
‪‪−1.70 M‬‬
‪0.00‬
Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−30.00 M‬‬
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
‪‪90.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:Aug 18, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪−0.08‬
‪−0.06‬
‪−0.04‬
‪−0.02‬
‪0.00‬
Actual
Estimate

ATOS news



No news here

Looks like there's nothing to report right now

Reload

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where ATOS is featured.

See all sparks 

Frequently Asked Questions


The current price of ATOS is 0.9066 USD — it has increased by 0.73% in the past 24 hours. Watch Atossa Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Atossa Therapeutics, Inc. stocks are traded under the ticker ATOS.
ATOS stock has risen by 8.70% compared to the previous week, the month change is a −0.02% fall, over the last year Atossa Therapeutics, Inc. has showed a −22.25% decrease.
We've gathered analysts' opinions on Atossa Therapeutics, Inc. future price: according to them, ATOS price has a max estimate of 7.50 USD and a min estimate of 4.00 USD. Watch ATOS chart and read a more detailed Atossa Therapeutics, Inc. stock forecast: see what analysts think of Atossa Therapeutics, Inc. and suggest that you do with its stocks.
ATOS reached its all-time high on Mar 19, 2013 with the price of 2,231.7764 USD, and its all-time low was 0.5000 USD and was reached on Dec 28, 2022. View more price dynamics on ATOS chart.
See other stocks reaching their highest and lowest prices.
ATOS stock is 5.75% volatile and has beta coefficient of 2.39. Track Atossa Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Atossa Therapeutics, Inc. there?
Today Atossa Therapeutics, Inc. has the market capitalization of ‪116.25 M‬, it has increased by 1.21% over the last week.
Yes, you can track Atossa Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Atossa Therapeutics, Inc. is going to release the next earnings report on Aug 18, 2025. Keep track of upcoming events with our Earnings Calendar.
ATOS earnings for the last quarter are −0.05 USD per share, whereas the estimation was −0.06 USD resulting in a 11.77% surprise. The estimated earnings for the next quarter are −0.06 USD per share. See more details about Atossa Therapeutics, Inc. earnings.
Atossa Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ATOS net income for the last quarter is ‪−6.72 M‬ USD, while the quarter before that showed ‪−6.35 M‬ USD of net income which accounts for −5.85% change. Track more Atossa Therapeutics, Inc. financial stats to get the full picture.
No, ATOS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 10, 2025, the company has 15 employees. See our rating of the largest employees — is Atossa Therapeutics, Inc. on this list?
Like other stocks, ATOS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Atossa Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Atossa Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Atossa Therapeutics, Inc. stock shows the sell signal. See more of Atossa Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.